← Human Trials & Peer-Reviewed Studies
Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial
Plain-language guide to PMID 40100350 (2025): randomized controlled trial study of Teriparatide in 64 patients.
Key Facts
- PMID
- 40100350
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Park JH et al. (7 authors)
- DOI
- 10.1007/s00198-025-07449-6
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide in this randomized controlled trial publication.
Teriparatide (experimental group) and denosumab (active control) were administered.
Who Took Part
According to the abstract, 64 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups.
Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication.
How the Study Was Run
The design is described as randomized.
The patients were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
The methods mention a period of 1 year.
The primary outcome was PJK and PJF incidence within 1 year after ASD surgery.
The secondary outcomes were patient-reported outcomes (PROs), bone mineral density (BMD), and dual-energy X-ray absorptiometry (DEXA) t-score of the hip.
What Was Measured
Topics PubMed links to this paper include Teriparatide, Bone Density Conservation Agents, Kyphosis, Osteoporosis, Thoracic Vertebrae, Denosumab and Lumbar Vertebrae.
Author keywords: Adult spinal deformity, PJF and PJK.
What This Means in Plain Language
The paper is a randomized study of Teriparatide in 64 patients over 1 year.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.